Fund
Euclidean Capital
Page built from the operations logged, not from a written profile. It says nothing about the fund's activity outside the scope of Bolus, which is health venture capital in Europe and the United States.
- Operations logged
- 4
- Lead
- 0
- New entries
- 4
- Follow ons
- 0
- Latest operation
- 16 September 2026
- Sectors
- Biotech
Operations
| Date | Company | Stage | Amount | Role |
|---|---|---|---|---|
| 16 Sept | United States, Biotech | Series D and later | 92,5 M$ | Participant |
| 17 Aug | United States, Biotech | Series A | 30 M$ | Participant |
| 12 Aug | United States | Series B | 77 M$ | Participant |
| 23 Jun | United States, Biotech | Series B | 73,8 M$ | Participant |
Co investors 17 funds crossed
- Eli Lilly and Company 3 operations
- The Column Group 3 operations
- Alexandria Venture Investments 1 operation
- Chugai Venture Fund 1 operation
- Emerson Collective 1 operation
- MRL Ventures Fund 1 operation
- Newpath Partners 1 operation
- Nextech Invest 1 operation
- OrbiMed 1 operation
- PhiFund 1 operation
- RA Capital Management 1 operation
- Samsara BioCapital 1 operation
- Sanofi 1 operation
- Sanofi Ventures 1 operation
- Solasta Ventures 1 operation
- SV Health Investors Dementia Discovery Fund 1 operation
- Vida Ventures 1 operation
Funds that appeared in the same rounds, in any capacity. Geographies logged: United States.